Advanced

Octreotide sc depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.

Tiberg, Fredrik; Roberts, John; Cervin, Camilla LU ; Johnsson, Markus; Sarp, Severine; Tripathi, Anadya Prakash and Linden, Margareta (2015) In British Journal of Clinical Pharmacology 80(3). p.460-472
Abstract
To assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of octreotide subcutaneous (sc) depot, a novel octreotide formulation.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Clinical Pharmacology
volume
80
issue
3
pages
460 - 472
publisher
John Wiley & Sons
external identifiers
  • pmid:26076191
  • wos:000360371900014
  • scopus:84940453766
ISSN
1365-2125
DOI
10.1111/bcp.12698
language
English
LU publication?
yes
id
01fd1213-c5b5-4f8f-b9e2-696353d06d9b (old id 7486161)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26076191?dopt=Abstract
date added to LUP
2015-07-08 16:09:03
date last changed
2017-10-08 03:02:46
@article{01fd1213-c5b5-4f8f-b9e2-696353d06d9b,
  abstract     = {To assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of octreotide subcutaneous (sc) depot, a novel octreotide formulation.},
  author       = {Tiberg, Fredrik and Roberts, John and Cervin, Camilla and Johnsson, Markus and Sarp, Severine and Tripathi, Anadya Prakash and Linden, Margareta},
  issn         = {1365-2125},
  language     = {eng},
  number       = {3},
  pages        = {460--472},
  publisher    = {John Wiley & Sons},
  series       = {British Journal of Clinical Pharmacology},
  title        = {Octreotide sc depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.},
  url          = {http://dx.doi.org/10.1111/bcp.12698},
  volume       = {80},
  year         = {2015},
}